Article Details

Theravance Finds Creative Solution to Recent Woes with $1.31B Royalty Payday

Retrieved on: 2022-07-14 19:02:23

Tags for this article:

Click the tags to see associated articles and topics

Theravance Finds Creative Solution to Recent Woes with $1.31B Royalty Payday. View article details on hiswai:

Excerpt

On Wednesday, top biopharma funder Royalty Pharma announced that it has agreed to purchase royalty interest in the inhaler drug Trelegy Ellipta from ...

Article found on: www.biospace.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up